Abbott Laboratories (ABT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 124.71 |
| Open | 126.81 |
| Bid | 125.43 x 1300 |
| Ask | 125.87 x 800 |
| Day's Range | 124.86 - 127.09 |
| 52 Week Range | 105.36 - 142.60 |
| Volume | |
| Avg. Volume | 5,515,785 |
| Market Cap | 222.504B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | 31.22 |
| EPS (TTM) | 4.03 |
| Earnings Date | Jan 26, 2022 |
| Forward Dividend & Yield | 1.88 (1.49%) |
| Ex-Dividend Date | Jan 13, 2022 |
| 1y Target Est | 145.18 |
Fair Value
Related Research
- Abbott LaboratoriesWeekly Stock ListThis is among our most-important themes for 2022, and stretches across industries. We think companies that raise their dividends consistently at a double-digit rate are sending off three important signals amid all the recent market volatility: 1) the company's balance sheet is strong enough to pay a dividend; 2) management is focused on providing shareholder returns; and 3) management is confident enough in the near-term outlook to raise the payout aggressively. This third factor is especially important as the pandemic upends the nation's recent record of long-term economic growth. Here are 12 stocks that meet our double-digit dividend test and are on the Argus BUY list. They are also holdings in our Dividend Growth Separately Managed Account and in the Dividend Growers Total Return Trust, sponsored by SmartTrust.RatingFair ValueEconomic Moat12 days agoArgus Research
- GuruFocus.com
Harrington Investments, INC Buys Pfizer Inc, AerCap Holdings NV, Sells Chubb, Abbott ...
Investment company Harrington Investments, INC (Current Portfolio) buys Pfizer Inc, AerCap Holdings NV, sells Chubb, Abbott Laboratories, JPMorgan Chase, Danaher Corp, Shopify Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Harrington Investments, INC.
- Motley Fool
3 Things About Abbott Laboratories That Smart Investors Know
When it comes to underrated healthcare stocks that smart investors love, Abbott Laboratories (NYSE: ABT) takes the cake. On the contrary, it's exactly Abbott's willingness to compete in these spaces that makes the company one of the sturdiest. Given that Abbott has a market cap of about $238 billion and trailing revenue of $42.3 billion, it shouldn't surprise anyone that the business sometimes struggles to grow as aggressively as a smaller competitor might.
- Zacks
Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings
With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.
